

**SUPPLEMENTAL TABLES:****Supplemental Table 1: Distribution of disease volume by BMI group**

	Underweight/Normal (BMI <25)		Overweight (25≤BMI<30)		Obesity (BMI ≥30)	
	N	Percent	N	Percent	N	Percent
Extent of Disease						
High	104	78.8%	221	66.8%	186	57.4%
Low	28	21.2%	110	33.2%	138	42.6%
Total	132		331		324	

\*Baseline BMI is significantly associated with disease volume ( $p < .0001$  by Fisher's exact test).

**Supplemental Table 2: Cox regression model<sup>1</sup> for time to CRPC**

Variable	UVA (n=788 <sup>2</sup> )			MVA <sup>3</sup> (n=788 <sup>2</sup> )		
	HR	95% CI	p-value	HR	95% CI	p-value
Treatment arm						
ADT alone	1.00	-		1.00	-	
ADT + D	0.61	(0.52, 0.73)	<.0001	0.60	(0.50, 0.71)	<.0001
Metformin use						
No	1.00	-		1.00	-	
Yes	0.87	(0.64, 1.18)	0.37	1.02	(0.75, 1.39)	0.91
Volume of disease						
Low	1.00	-		1.00	-	
High	2.20	(1.80, 2.68)	<.0001	1.93	(1.57, 2.38)	<.0001
ECOG PS						
0	1.00	-		-	-	-
1-2	1.15	(0.95, 1.39)	0.15	-	-	-
Gleason score						
≤7	1.00	-		1.00	-	
8-10	1.52	(1.23, 1.87)	<.0001	1.30	(1.04, 1.62)	0.02
Missing/Unknown	1.55	(1.13, 2.13)	0.007	1.17	(0.84, 1.63)	0.35
Prior local therapy						
No	1.00	-		1.00	-	
Yes	0.58	(0.47, 0.73)	<.0001	0.64	(0.50, 0.83)	0.0007
Baseline PSA						
<65	1.00	-		1.00	-	
≥65	1.46	(1.22, 1.75)	<.0001	1.27	(1.05, 1.54)	0.01
BMI						
<25	1.00	-		-	-	-
25-29.9	0.86	(0.67, 1.10)	0.22	-	-	-
≥30	0.89	(0.69, 1.14)	0.34	-	-	-

1. stratified by stratification factors at randomization, including age, ECOG PS, CAB use, duration of prior adjuvant hormonal therapy, use of FDA approved drugs for delaying skeletal related events and volume of disease; treatment arm by metformin use interaction was not statistically significant (p=0.42)
2. only patients with metformin data were included in the analysis
3. variables with p<0.10 in the univariable analysis were included in the multivariable analysis; metformin was forced into the multivariable model regardless of significance.